Issue link: https://www.e-digitaleditions.com/i/1496325
The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. 36 April 2023 Inhalation technology that uses a covalent heterobivalent inhibitor (cHBI) that binds in an allergen-specific manner as a preventive for allergic reactions. Building on results of their in vitro testing, they designed a humanized mouse model to test cHBI efficacy in vivo. Science Daily noted the researchers developed the inhibitors for peanut allergy because it is the most common food allergy, with high prevalence, especially in children. ere are currently few therapies for peanut allergy, other than strict dietary avoidance or oral immunotherapy, neither of which are successful in all patients. At the same time, the risk of accidental allergic exposure is high. e researchers also antic- ipate the technology platform can be used to develop inhibitors for a range of other allergens, such as shellfish and penicillin. Study results were published in Science Translational Medicine. Positive safety data from first-in-human study of novel inhaled macrocycle A L L S C H W I L , S W I T Z E R - LAND—Spexis has announced positive safety data from the first- in-human clinical trial of its orally inhaled antibiotic, murepavadin (iMPV), a novel macrocycle com- pound, reported European Phar- maceutical Review. Spexis defines macrocycles as a "chemical class of pharmaceutical therapeutics occu- pying the chemical space between small molecules and biologics." iMPV is also one of the first can- didates in the novel outer mem- brane protein targeting antibiotics (OMPTA) class. It targets Pseudo- monas aeruginosa, including highly resistant strains, the key pathogen in cystic fibrosis (CF) lung infec- tions. e Phase I trial was a single center, double-blind, randomized, placebo-controlled trial to inves- tigate the safety, tolerability and pharmacokinetics (PK) of single ascending doses of iMPV in 39 healthy volunteers. e novel mac- rocycle compound achieved high inhibiting concentrations in the lung airways of participants. Anal- yses of preliminary, blinded data showed that the macrocycle com- pound was well tolerated at all dose levels. No clinically relevant signs of irritation of the upper airways and no serious adverse events (SAEs) were reported. Additional trials in patients with CF or non-CF bron- chiectasis are expected. CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations RESPIRATORY MEDICINE NEWS continued from page 8 Inhalationmag.com Use the article archive FREE with no registration required.